Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Randomized, double-blind, double-dummy, active-controlled, 4 period complete cross-over study to compare the effect on lung function of 6 weeks once daily treatment with orally inhaled tiotropium+olodaterol fixed dose combination delivered by the Respimat inhaler vs. 6 weeks twice daily treatment with fluticasone propionate+salmeterol fixed dose combination delivered by the Accuhaler in patients with Chronic Obstructive Pulmonary Disease (COPD)

Next Previous
X
Search
Trial Profile

Randomized, double-blind, double-dummy, active-controlled, 4 period complete cross-over study to compare the effect on lung function of 6 weeks once daily treatment with orally inhaled tiotropium+olodaterol fixed dose combination delivered by the Respimat inhaler vs. 6 weeks twice daily treatment with fluticasone propionate+salmeterol fixed dose combination delivered by the Accuhaler in patients with Chronic Obstructive Pulmonary Disease (COPD)

Status: Completed
Phase of Trial: Phase III

Latest Information Update: 27 Dec 2021

Price :

$35 *

Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Olodaterol/tiotropium bromide (Primary) ; Salmeterol/fluticasone propionate
  • Indications Chronic obstructive pulmonary disease
  • Focus Registrational; Therapeutic Use
  • Acronyms ENERGITO; TOviTO
  • Sponsors Boehringer Ingelheim Pharmaceuticals

    • Most Recent Events

    • 09 Feb 2016 Results published in Journal of Chronic Obstructive Pulmonary Disease (COPD), as per Boehringer Ingelheim media release.
    • 09 Feb 2016 Results published in Boehringer Ingelheim media release.
    • 28 Sep 2015 Primary endpoint has been met (FEV1 AUC0-12h - change from baseline after 6 weeks of treatment), according to a Boehringer Ingelheim media release.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top